Poplar-type Propolis Dry Extract ESIT12 : Nutrikinetic and Bioavailability Studies - Trial NCT06062511
Access comprehensive clinical trial information for NCT06062511 through Pure Global AI's free database. This phase not specified trial is sponsored by Fytexia and is currently Recruiting. The study focuses on Nutrition, Healthy. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fytexia
Timeline & Enrollment
N/A
Jul 22, 2023
Oct 06, 2023
Primary Outcome
Change in plasma area under the curve (AUC) of phenolic metabolites after acute ingestion of the supplement/placebo,Change in plasma maximal concentration (Cmax) of phenolic metabolites after acute ingestion of the supplement/placebo,Change in plasma time to reach maximal concentration (Tmax) of phenolic metabolites after acute ingestion of the supplement/placebo,Change in urine area under the curve (AUC) phenolic metabolites excretion after acute ingestion of the supplement/placebo,Change in urine maximal concentration (Cmax) phenolic metabolites excretion after acute ingestion of the supplement/placebo,Change in urine time to reach maximal concentration (Tmax) phenolic metabolites excretion after acute ingestion of the supplement/placebo
Summary
The aim of this study is to investigate phenolic compounds from ESIT12, a poplar-type
 propolis ingredient, bioavailability and nutrikinetics by measuring urinary excretion and
 metabolic profile over 48h by means of high-performance liquid chromatography coupled with
 tandem mass spectrometry (HPLC-MS/MS). The study follows a cross-over, double-blind,
 randomized and placebo control design on 10 healthy subjects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06062511
Non-Device Trial